NCT05645172Active, not recruiting
Retention Rate of Acalabrutinib in a Non-interventional Setting
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 193 (actual)
- First submitted
- 10 Nov 2022
- Start date
- 12 Dec 2022
- Primary completion date
- 15 Apr 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT05645172
What you commit to
- Study type: Observational
- Participants enrolled: 193
- From 12 Dec 2022 to the primary completion date, 15 Apr 2027
- 54 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to treatment with acalabrutinib according to the current SmPC
- Disease progression on prior BTKi therapy
- Start of acalabrutinib therapy more than 28 days prior to enrolment
Other
- Current or planned participation in an interventional clinical trial
- Pregnancy or breast feeding
Who the study is looking for
- Age ≥ 18 years
- Diagnosis of CLL
- Ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives
- Decision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy.
- Provision of signed informed consent form
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (54)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.